Search
Results: 9850
Best practice in Active Surveillance for men with prostate cancer
Samuel WD Merriel, Liz Hetherington, Andrew Seggie, Joanna T Castle, William Cross, Monique J Roobol, Vincent Gnanapragasam, Caroline M Moore, Prostate Cancer UK Expert Reference Group on Active Surveillance
Apr 04, 2019
OBJECTIVES: To develop a consensus statement on current best practice of active surveillance (AS) in the UK, informed by patients and clinical experts. SUBJECTS AND METHODS: A consensus statement was drafted on the basis of...
Homeobox B13 G84E Mutation and Prostate Cancer Risk.
Tommy Nyberg, Koveela Govindasami, Goska Leslie, Tokhir Dadaev, Elizabeth Bancroft, Holly Ni Raghallaigh, Mark N Brook, Nafisa Hussain, Diana Keating, Andrew Lee, Romayne McMahon, Angela Morgan, Andrea Mullen, Andrea Osborne, Reshma Rageevakumar, UK Genetic Prostate Cancer Study Collaborators, Zsofia Kote-Jarai, Rosalind Eeles, Antonis C Antoniou
Dec 19, 2018
BACKGROUND: The homeobox B13 (HOXB13) G84E mutation has been recommended for use in genetic counselling for prostate cancer (PCa), but the magnitude of PCa risk conferred by this mutation is uncertain. OBJECTIVE: To obtain...
Comparative performance and external validation of the multivariable PREDICT Prostate tool for non-metastatic prostate cancer
Abstract: Background: PREDICT Prostate is an endorsed prognostic model that provides individualised long-term prostate cancer-specific and overall survival estimates. The model, derived from UK data, estimates potential...
Comparative performance and external validation of the multivariable PREDICT Prostate tool for non-metastatic prostate cancer
Abstract: Background: PREDICT Prostate is an endorsed prognostic model that provides individualised long-term prostate cancer-specific and overall survival estimates. The model, derived from UK data, estimates potential...
Comparative performance and external validation of the multivariable PREDICT Prostate tool for non-metastatic prostate cancer
Abstract: Background: PREDICT Prostate is an endorsed prognostic model that provides individualised long-term prostate cancer-specific and overall survival estimates. The model, derived from UK data, estimates potential...
Consensus for genes to be included on cancer panel tests offered by UK genetics services
Amy Taylor, Angela F Brady, Ian M Frayling, Helen Hanson, Marc Tischkowitz, Clare Turnbull, Lucy Side, UK Cancer Genetics Group (UK-CGG)
May 18, 2018
Genetic testing for hereditary cancer predisposition has evolved rapidly in recent years with the discovery of new genes, but there is much debate over the clinical utility of testing genes for which there are currently limited...
The architecture of clonal expansions in morphologically normal tissue from cancerous and non-cancerous prostates.
Claudia Buhigas, Anne Y Warren, Wing-Kit Leung, Hayley C Whitaker, Hayley J Luxton, Steve Hawkins, Jonathan Kay, Adam Butler, Yaobo Xu, Dan J Woodcock, Sue Merson, Fiona M Frame, Atef Sahli, Federico Abascal, CRUK-ICGC Prostate Cancer Group, Iñigo Martincorena, G Steven Bova, Christopher S Foster, Peter Campbell, Norman J Maitland, David E Neal, Charlie E Massie, Andy G Lynch, Rosalind A Eeles, Colin S Cooper, David C Wedge, Daniel S Brewer
Sep 22, 2022
BACKGROUND: Up to 80% of cases of prostate cancer present with multifocal independent tumour lesions leading to the concept of a field effect present in the normal prostate predisposing to cancer development. In the present...
Pan-cancer analysis of whole genomes.
Cancer is driven by genetic change, and the advent of massively parallel sequencing has enabled systematic documentation of this variation at the whole-genome scale1-3. Here we report the integrative analysis of...
Cell Proliferation Cellular Senescence Chromothripsis Cloud Computing DNA Mutational Analysis evolution Molecular Female Genome Human Genomics Germ-Line Mutation High-Throughput Nucleotide Sequencing Humans Information Dissemination Male Mutagenesis Mutation Neoplasms Oncogenes Promoter Regions Genetic RNA Splicing Reproducibility of Results Telomerase Telomere
The architecture of clonal expansions in morphologically normal tissue from cancerous and non-cancerous prostates.
Claudia Buhigas, Anne Y Warren, Wing-Kit Leung, Hayley C Whitaker, Hayley J Luxton, Steve Hawkins, Jonathan Kay, Adam Butler, Yaobo Xu, Dan J Woodcock, Sue Merson, Fiona M Frame, Atef Sahli, Federico Abascal, CRUK-ICGC Prostate Cancer Group, Iñigo Martincorena, G Steven Bova, Christopher S Foster, Peter Campbell, Norman J Maitland, David E Neal, Charlie E Massie, Andy G Lynch, Rosalind A Eeles, Colin S Cooper, David C Wedge, Daniel S Brewer
Oct 24, 2022
BACKGROUND: Up to 80% of cases of prostate cancer present with multifocal independent tumour lesions leading to the concept of a field effect present in the normal prostate predisposing to cancer development. In the present...
Risk stratification for prostate cancer management
M. G. Parry, T. E. Cowling, A. Sujenthiran, J. Nossiter, B. Berry, P. Cathcart, A. Aggarwal, H. Payne, J. van der Meulen, N. W. Clarke, V. J. Gnanapragasam
Jun 06, 2020
Abstract: Background: The five-tiered Cambridge Prognostic Group (CPG) classification is a better predictor of prostate cancer-specific mortality than the traditional three-tiered classification (low, intermediate, and high...
Prostate cancer in South Africa
Prostate cancer is one of the most common male cancers globally; however little is known about prostate cancer in Africa. Incidence data for prostate cancer in South Africa (SA) from the pathology based National Cancer Registry...
Understanding of prognosis in non-metastatic prostate cancer
PREDICT Prostate is an individualised prognostic model that provides long-term survival estimates for men diagnosed with non-metastatic prostate cancer ( www.prostate.predict.nhs.uk ). In this study clinician estimates of...
Germline variation at 8q24 and prostate cancer risk in men of European ancestry.
Marco Matejcic, Edward J Saunders, Tokhir Dadaev, Mark N Brook, Kan Wang, Xin Sheng, Ali Amin Al Olama, Fredrick R Schumacher, Sue A Ingles, Koveela Govindasami, Sara Benlloch, Sonja I Berndt, Demetrius Albanes, Stella Koutros, Kenneth Muir, Victoria L Stevens, Susan M Gapstur, Catherine M Tangen, Jyotsna Batra, Judith Clements, Henrik Gronberg, Nora Pashayan, Johanna Schleutker, Alicja Wolk, Catharine West, Lorelei Mucci, Peter Kraft, Géraldine Cancel-Tassin, Karina D Sorensen, Lovise Mæhle, Eli M Grindedal, Sara S Strom, David E Neal, Freddie C Hamdy, Jenny L Donovan, Ruth C Travis, Robert J Hamilton, Barry Rosenstein, Yong-Jie Lu, Graham G Giles, Adam S Kibel, Ana Vega, Jeanette T Bensen, Manolis Kogevinas, Kathryn L Penney, Jong Y Park, Janet L Stanford, Cezary Cybulski, Børge G Nordestgaard, Hermann Brenner, Christiane Maier, Jeri Kim, Manuel R Teixeira, Susan L Neuhausen, Kim De Ruyck, Azad Razack, Lisa F Newcomb, Davor Lessel, Radka Kaneva, Nawaid Usmani, Frank Claessens, Paul A Townsend, Manuela Gago-Dominguez, Monique J Roobol, Florence Menegaux, Kay-Tee Khaw, Lisa A Cannon-Albright, Hardev Pandha, Stephen N Thibodeau, Daniel J Schaid, PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium, Fredrik Wiklund, Stephen J Chanock, Douglas F Easton, Rosalind A Eeles, Zsofia Kote-Jarai, David V Conti, Christopher A Haiman
Dec 18, 2018
Chromosome 8q24 is a susceptibility locus for multiple cancers, including prostate cancer. Here we combine genetic data across the 8q24 susceptibility region from 71,535 prostate cancer cases and 52,935 controls of European...
Risk stratification for prostate cancer management
M. G. Parry, T. E. Cowling, A. Sujenthiran, J. Nossiter, B. Berry, P. Cathcart, A. Aggarwal, H. Payne, J. van der Meulen, N. W. Clarke, V. J. Gnanapragasam
May 28, 2021
Abstract: Background: The five-tiered Cambridge Prognostic Group (CPG) classification is a better predictor of prostate cancer-specific mortality than the traditional three-tiered classification (low, intermediate, and high...
A core outcome set for localised prostate cancer effectiveness trials
S MacLennan, PR Williamson, H Bekema, M Campbell, C Ramsay, J N'Dow, S MacLennan, L Vale, P Dahm, N Mottet, T Lam, G Stewart, COMPACTERS Study Group
Jun 26, 2017
$\textbf{OBJECTIVE}$: To develop a core outcome set (COS) applicable for effectiveness trials of all interventions for localised prostate cancer. Many treatments exist for localised prostate cancer, although it is unclear which...
Understanding of prognosis in non-metastatic prostate cancer
Abstract: PREDICT Prostate is an individualised prognostic model that provides long-term survival estimates for men diagnosed with non-metastatic prostate cancer (www.prostate.predict.nhs.uk). In this study clinician estimates...
Height, selected genetic markers and prostate cancer risk
Artitaya Lophatananon, Sarah Stewart-Brown, Zsofia Kote-Jarai, Ali Amin Al Olama, Sara Benlloch Garcia, David E Neal, Freddie C Hamdy, Jenny L Donovan, Graham G Giles, Liesel M Fitzgerald, Melissa C Southey, Paul Pharoah, Nora Pashayan, Henrik Gronberg, Fredrik Wiklund, Markus Aly, Janet L Stanford, Hermann Brenner, Aida K Dieffenbach, Volker Arndt, Jong Y Park, Hui-Yi Lin, Thomas Sellers, Chavdar Slavov, Radka Kaneva, Vanio Mitev, Jyotsna Batra, Amanda Spurdle, Judith A Clements, APCB BioResource, PRACTICAL Consortium, Douglas Easton, Rosalind A Eeles, Kenneth Muir
Dec 08, 2017
BACKGROUND: Evidence on height and prostate cancer risk is mixed, however, recent studies with large data sets support a possible role for its association with the risk of aggressive prostate cancer. METHODS: We analysed data...
Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue.
Colin S Cooper, Rosalind Eeles, David C Wedge, Peter Van Loo, Gunes Gundem, Ludmil B Alexandrov, Barbara Kremeyer, Adam Butler, Andrew G Lynch, Niedzica Camacho, Charlie E Massie, Jonathan Kay, Hayley J Luxton, Sandra Edwards, Zsofia Kote-Jarai, Nening Dennis, Sue Merson, Daniel Leongamornlert, Jorge Zamora, Cathy Corbishley, Sarah Thomas, Serena Nik-Zainal, Sarah O'Meara, Lucy Matthews, Jeremy Clark, Rachel Hurst, Richard Mithen, Robert G Bristow, Paul C Boutros, Michael Fraser, Susanna Cooke, Keiran Raine, David Jones, Andrew Menzies, Lucy Stebbings, Jon Hinton, Jon Teague, Stuart McLaren, Laura Mudie, Claire Hardy, Elizabeth Anderson, Olivia Joseph, Victoria Goody, Ben Robinson, Mark Maddison, Stephen Gamble, Christopher Greenman, Dan Berney, Steven Hazell, Naomi Livni, ICGC Prostate Group, Cyril Fisher, Christopher Ogden, Pardeep Kumar, Alan Thompson, Christopher Woodhouse, David Nicol, Erik Mayer, Tim Dudderidge, Nimish C Shah, Vincent Gnanapragasam, Thierry Voet, Peter Campbell, Andrew Futreal, Douglas Easton, Anne Y Warren, Christopher S Foster, Michael R Stratton, Hayley C Whitaker, Ultan McDermott, Daniel S Brewer, David E Neal
Nov 01, 2018
Genome-wide DNA sequencing was used to decrypt the phylogeny of multiple samples from distinct areas of cancer and morphologically normal tissue taken from the prostates of three men. Mutations were present at high levels in...
Polygenic hazard score is associated with prostate cancer in multi-ethnic populations.
Minh-Phuong Huynh-Le, Chun Chieh Fan, Roshan Karunamuni, Wesley K Thompson, Maria Elena Martinez, Rosalind A Eeles, Zsofia Kote-Jarai, Kenneth Muir, Johanna Schleutker, Nora Pashayan, Jyotsna Batra, Henrik Grönberg, David E Neal, Jenny L Donovan, Freddie C Hamdy, Richard M Martin, Sune F Nielsen, Børge G Nordestgaard, Fredrik Wiklund, Catherine M Tangen, Graham G Giles, Alicja Wolk, Demetrius Albanes, Ruth C Travis, William J Blot, Wei Zheng, Maureen Sanderson, Janet L Stanford, Lorelei A Mucci, Catharine ML West, Adam S Kibel, Olivier Cussenot, Sonja I Berndt, Stella Koutros, Karina Dalsgaard Sørensen, Cezary Cybulski, Eli Marie Grindedal, Florence Menegaux, Kay-Tee Khaw, Jong Y Park, Sue A Ingles, Christiane Maier, Robert J Hamilton, Stephen N Thibodeau, Barry S Rosenstein, Yong-Jie Lu, Stephen Watya, Ana Vega, Manolis Kogevinas, Kathryn L Penney, Chad Huff, Manuel R Teixeira, Luc Multigner, Robin J Leach, Lisa Cannon-Albright, Hermann Brenner, Esther M John, Radka Kaneva, Christopher J Logothetis, Susan L Neuhausen, Kim De Ruyck, Hardev Pandha, Azad Razack, Lisa F Newcomb, Jay H Fowke, Marija Gamulin, Nawaid Usmani, Frank Claessens, Manuela Gago-Dominguez, Paul A Townsend, William S Bush, Monique J Roobol, Marie-Élise Parent, Jennifer J Hu, Ian G Mills, Ole A Andreassen, Anders M Dale, Tyler M Seibert, UKGPCS collaborators, APCB (Australian Prostate Cancer BioResource), NC-LA PCaP Investigators, IMPACT Study Steering Committee and Collaborators, Canary PASS Investigators, Profile Study Steering Committee, PRACTICAL Consortium
Feb 23, 2021
Genetic models for cancer have been evaluated using almost exclusively European data, which could exacerbate health disparities. A polygenic hazard score (PHS1) is associated with age at prostate cancer diagnosis and improves...
The genomic evolution of human prostate cancer.
Prostate cancers are highly prevalent in the developed world, with inheritable risk contributing appreciably to tumour development. Genomic heterogeneity within individual prostate glands and between patients derives...
Diagnosing cancer in primary care
Ruth Swann, Sean McPhail, Jana Witt, Brian Shand, Gary A Abel, Sara Hiom, Jem Rashbass, Georgios Lyratzopoulos, Greg Rubin, National Cancer Diagnosis Audit Steering Group
Mar 07, 2018
BACKGROUND: Continual improvements in diagnostic processes are needed to minimise the proportion of patients with cancer who experience diagnostic delays. Clinical audit is a means of achieving this. AIM: To characterise key...
Systematic review and meta-analysis of the associations between body mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigen.
Sean Harrison, Kate Tilling, Emma L Turner, Richard M Martin, Rosie Lennon, J Athene Lane, Jenny L Donovan, Freddie C Hamdy, David E Neal, JLH Ruud Bosch, Hayley E Jones
Mar 11, 2021
PURPOSE: The relationship between body mass index (BMI) and prostate cancer remains unclear. However, there is an inverse association between BMI and prostate-specific antigen (PSA), used for prostate cancer screening. We...
Systematic review and meta-analysis of the associations between body mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigen
Sean Harrison, Kate Tilling, Emma L. Turner, Richard M. Martin, Rosie Lennon, J. Athene Lane, Jenny L. Donovan, Freddie C. Hamdy, David E. Neal, J. L. H. Ruud Bosch, Hayley E. Jones
Jun 06, 2020
Abstract: Purpose: The relationship between body mass index (BMI) and prostate cancer remains unclear. However, there is an inverse association between BMI and prostate-specific antigen (PSA), used for prostate cancer screening....
Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer.
Young Seok Ju, Ludmil B Alexandrov, Moritz Gerstung, Inigo Martincorena, Serena Nik-Zainal, Manasa Ramakrishna, Helen R Davies, Elli Papaemmanuil, Gunes Gundem, Adam Shlien, Niccolo Bolli, Sam Behjati, Patrick S Tarpey, Jyoti Nangalia, Charles E Massie, Adam P Butler, Jon W Teague, George S Vassiliou, Anthony R Green, Ming-Qing Du, Ashwin Unnikrishnan, John E Pimanda, Bin Tean Teh, Nikhil Munshi, Mel Greaves, Paresh Vyas, Adel K El-Naggar, Tom Santarius, V Peter Collins, Richard Grundy, Jack A Taylor, D Neil Hayes, David Malkin, ICGC Breast Cancer Group, ICGC Chronic Myeloid Disorders Group, ICGC Prostate Cancer Group, Christopher S Foster, Anne Y Warren, Hayley C Whitaker, Daniel Brewer, Rosalind Eeles, Colin Cooper, David Neal, Tapio Visakorpi, William B Isaacs, G Steven Bova, Adrienne M Flanagan, P Andrew Futreal, Andy G Lynch, Patrick F Chinnery, Ultan McDermott, Michael R Stratton, Peter J Campbell
Nov 01, 2018
Recent sequencing studies have extensively explored the somatic alterations present in the nuclear genomes of cancers. Although mitochondria control energy metabolism and apoptosis, the origins and impact of cancer-associated...
cancer genome evolution evolutionary biology Genomics human Mitochondrial DNA mutational signature SEQUENCING Somatic mutation Animals Base Composition DNA DNA Replication DNA Mitochondrial DNA Neoplasm Data Mining evolution Molecular Genome Mitochondrial High-Throughput Nucleotide Sequencing Humans Mitochondria Mutation Neoplasms Polymorphism Single Nucleotide
Active surveillance of prostate cancer
BACKGROUND: Active surveillance is considered a mainstream strategy in the management of patients with low-risk prostate cancer. A mission-critical step in implementing a robust active surveillance program and plan its resource...
|
|< |
< |
1 |